Lower risk of liver cancer in patients with schizophrenia: a systematic review and meta-analysis of cohort studies

Dali Xu, Guangdong Chen, Lingguang Kong, Wei Zhang, Lirong Hu, Ce Chen, Jie Li and Chuanjun Zhuo _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102328-102335. https://doi.org/10.18632/oncotarget.21679

Metrics: PDF 675 views  |   HTML 1058 views  |   ?  


Dali Xu1,*, Guangdong Chen1,*, Lingguang Kong1,*, Wei Zhang1, Lirong Hu1, Ce Chen1, Jie Li2 and Chuanjun Zhuo1,2

1Department of Psychiatry, Wenzhou Seventh People’s Hospital, Wenzhou, 325000, China

2Department of Psychiatry, Tianjin Anding Hospital, Tianjin Mental Health Center, Tianjin, 300222, China

*These authors contributed equally to this work

Correspondence to:

Chuanjun Zhuo, email: chuanjunzhuotjmh@163.com

Keywords: schizophrenia, liver cancer, incidence, cohort study, systematic review

Received: August 09, 2017     Accepted: September 22, 2017     Published: October 09, 2017


Previous studies regarding the association between schizophrenia and the subsequent risk of liver cancer have shown inconsistent results. We aimed to perform a systematic review and meta-analysis to evaluate the association between schizophrenia and liver cancer incidence. We systematically searched the PubMed and Embase electronic databases for cohort studies reporting the standardized incidence ratio (SIR) for the risk of liver cancer in patents with schizophrenia as compared with the general population. A random-effects model was used to analyze the data. Stratified analyses were performed according to the gender of the patients. Seven studies comprising 312,834 patients with schizophrenia were included. During follow-up, 581 liver cancer cases were confirmed. The meta-analysis results showed that schizophrenia was associated with a trend of a lower liver cancer incidence (SIR: 0.83, 95% confidence interval [CI]: 0.66–1.04, p = 0.10) with significant heterogeneity (I2 = 81%). Sensitivity analysis of five cohorts of patients with cancer events before the diagnosis of schizophrenia indicated that schizophrenia was associated with a significantly lower incidence of liver cancer (SIR: 0.76, 95% CI: 0.61–0.96, p = 0.02; I2 = 84%). The reduction of a subsequent incidence of liver cancer was significant in male patients with schizophrenia (SIR: 0.71, p = 0.005), and a trend of a reduced risk of liver cancer was also detected in female patients (SIR: 0.83, p = 0.12). Significant publication bias was detected. However, “trim and fill” analyses by including the imputed unpublished studies showed similar results. In summary, schizophrenia may be protective against the incidence of liver cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21679